Preclinical study identifies Rb1 deficiency as key therapeutic vulnerability in a subset of breast cancers resistant to standard CDK4/6 inhibitors Drugs that may exploit this vulnerability are already ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback